Delivery Order SPE2DB22D3301-SPE2DB25FZ1AM
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $10,627.40 to AmerisourceBergen Drug Corp for BIKTARVY 50-200-25 mg tablets (30-count units) on August 18, 2025, with completion scheduled for August 19, 2025. This firm fixed-price, competitively awarded contract with no set-aside designation leverages AmerisourceBergen's position as a major pharmaceutical distributor supporting federal medical procurement. The work will be performed at the company's corporate office in...
- The Defense Logistics Agency awarded a $46,648.39 delivery order to AmerisourceBergen Drug Corp on June 16, 2025, for the supply of BIKTARVY 50-200-25 mg tablets in quantities of 30 units. This is a firm fixed-price contract with a completion date of June 17, 2025, and represents a non-set-aside award. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location in the same city. This delivery order is...
- The Defense Logistics Agency awarded a delivery order valued at $36,245.57 to AmerisourceBergen Drug Corp for BIKTARVY 50-200-25 mg tablets (30-count units) on July 28, 2025, with completion scheduled for July 29, 2025. This competitive, firm fixed-price delivery order was placed under a non-set-aside procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, with particular emphasis on...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $8,605.11 on August 12, 2025, for the supply of BIKTARVY 50-200-25 mg tablets (30-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 13, 2025. The contract represents a pharmaceutical delivery under the company's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and...
- The Defense Logistics Agency awarded a delivery order valued at $60,535.69 to AmerisourceBergen Drug Corp for the supply of BIKTARVY 50-200-25 mg tablets (30-count units). This firm fixed price contract, awarded on August 28, 2025, with an ultimate completion date of August 29, 2025, represents a competitive award with no set-aside designation. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under the company's...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp for the supply of BIKTARVY 50-200-25 mg tablets (30-count bottles) valued at $6,865.44. This competitive, non-set-aside contract represents a firm fixed price delivery order with an ultimate completion date of August 14, 2025, and was executed on August 13, 2025. The contract is fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order valued at $50,771.82 to AmerisourceBergen Drug Corp for BIKTARVY 50-200-25 mg tablets (30-unit supply) on August 11, 2025, with a completion date of August 12, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child order under the company's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $11,608.50 to AmerisourceBergen Drug Corp for BIKTARVY 50-200-25 mg tablets (30-count units) on August 7, 2025, with an ultimate completion date of August 8, 2025. This firm fixed-price, non-set-aside contract is performed at the contractor's Conshohocken, Pennsylvania location. The award represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of BIKTARVY 50-200-25 mg tablets in quantities of 30 units. This is a firm fixed-price delivery order with a ceiling value of $148,306.62 and an ultimate completion date of September 3, 2025. The contract carries no set-aside designation, indicating it was competitively awarded. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a delivery order valued at $73,229.67 to AmerisourceBergen Drug Corp for BIKTARVY 50-200-25 mg tablets (30-count units) on August 13, 2025, with completion targeted for August 14, 2025. This firm fixed-price delivery order, which carries no set-aside designation, represents a competitively awarded contract fulfilling federal pharmaceutical procurement requirements. The award was placed to AmerisourceBergen's Corporate Office located in Conshohocken,...
- SPE2DB22D3301Indefinite Delivery Contract
- SPE2DB22D3301-SPE2DB25FZ1AMDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $8,714.12 to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of BIKTARVY 50-200-25 mg tablets (30-count units). This is a firm fixed-price delivery order with no set-aside designation, and represents a competitively awarded procurement. The contract was executed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999 and extends through December 2026. This prime contract vehicle serves as a comprehensive global pharmaceutical support mechanism enabling AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement supporting military and veteran healthcare systems. The company's federal contract portfolio demonstrates extensive experience delivering brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains. The underlying SPE2DX vehicle reflects DLA's strategic approach to pharmaceutical procurement, providing flexible access to a comprehensive range of medical products needed to support defense health operations globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.7k | 9/16/25 |